Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundational treatment in curative-intent settings of HER2 ...
Thinking about what to do with your Daiichi Sankyo Company shares? If you are watching your stocks closely or hunting for opportunities, you have probably noticed this name keeps popping up on analyst ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval for their second antibody-drug conjugate (ADC) cancer treatment, Datroway, the partners have secured a seventh nod for their ...
Daiichi Sankyo is taking another big step in its transformation to oncology drugmaker. The pharma company recently laid out plans to create an integrated oncology business unit, tapping current U.S.
Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is ...
Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for the supplemental biologics licence application (sBLA) of Enhertu (fam-trastuzumab ...
TOKYO, March 12 (Reuters) - Daiichi Sankyo <4568.T>, Japan's third-largest drugmaker, said on Friday it aims to nearly double its annual operating profit and increase revenue by a fifth in three years ...
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed with ...
AstraZeneca and Daiichi Sankyo's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback